



Ghent University

Evaluation of CO₂-absorbents for Use in Sevoflurane Based Closed-circuit Anesthesia through GC-MS Determination of Compound A

Marie-Paule L. A. Bouche¹

L.F. Versichelen², M.M. Struys², E.P. Mortier², G. Rolly²,
A.P. De Leenheer¹, and J.F. Van Bocxlaer¹

¹ Laboratory of Medical Biochemistry and Toxicology, Ghent University, Belgium

² Department of Anesthesiology, University Hospital, Ghent University, Belgium



Outline


- Introduction
- Aim
- Development of the analytical procedure
- Method validation
- Application in clinical trial
- Conclusions



Introduction

- Sevoflurane: **widespread use** as inhalational anesthetic

- Volatile, non-flammable, non-explosive
- Pleasant smell
- Low blood and tissue solubility



- smooth **induction** of anesthesia
- rapid **recovery** from anesthesia
- more **precise control** of anesthesia

- **Ideal** anesthetic ?



- However:

- **Metabolization** in-vivo (2-5%)

- HFIP

- Inorganic F^- : nephrotoxic

- **Interaction and degradation** by **CO₂-absorbents**


- Used in low-flow and closed-circuit anesthesia to sequester CO₂ exhaled by the patient

e.g. sodalime,
Baralyme[®]

⇒ Formation of **potentially toxic** by-products



■ Compound A:



➤ **Known nephrotoxic** in rats

- **LC₅₀**: 120-1100 ppm
- **Threshold** for nephrotoxicity: 50-114 ppm



- **Parameters** affecting compound A production
 - Sevoflurane concentration
 - Chemical composition of absorbent
 - Fresh gas flow rate
 - Temperature → CO₂ production
 - Duration of anesthesia
 - Water content

 - **FDA restriction**: fresh gas flows < 2 L/min

 - **Reports** in the literature:
 - 20-30 ppm
 - **compound A controversy**
- ⇒ **Is sevoflurane administration safe ?**



Aim

1. To assess “safe” sevoflurane administration in present day low-flow and closed-circuit anesthesia
2. Development of an analytical assay for quantitative determination of trace levels of compound A in vapour phase samples



Development

- **Requirements** for the assay
 - Very limited sample volume (1-2 mL)
 - Automation
 - Complete resolution between compound A and sevoflurane
 - Sensitivity
 - Easy-to-perform calibration procedure



■ Injection procedure

➤ Challenge:

Maximum sensitivity

High injection volume:

1 mL

High chromatographic peak quality:

Small initial bandwidth

Reconciliation in capillary GC ?



■ Injection procedure

- Based upon automated headspace sampling
- PTV (Gerstel CIS-4)
- Cryogenic condensation in the injector liner followed by flash desorption (250 °C)
 - Liquid N₂, -80 °C
 - Tenax TA

⇒ Simple, robust and automated injection approach



■ Chromatographic separation

- Adequate retention and separation

⇒ Custom made CP-Select 624

Isothermal: 38 °C

■ Mass spectrometric detection


- Full-scan mode: 40 – 300 amu
- Identification based on T_R + Mass spectrum
- Quantification based on
reconstructed mass fragmentograms
(compound A, m/z 128)



■ Internal standard

- To enhance the precision
- **Choice:**
 - Physicochemical properties
 - Halogenated → xenobiotic
 - Good retention profile
 - Typical mass spectrum
- 1,1,1-trifluoro-2-iodoethane
- Addition: 0.5 µL injected into every vial





- Peak identification:
1. Compound A
 2. Sevoflurane
 3. Internal standard



■ Calibration procedure

- Easy-to-perform: **static method**
- **No** dedicated gas instrumentation
- 7 calibrators + **zero-calibrator**
- **Range**: 0 – 75 ppm or $\mu\text{L}/\text{L}$ compound A
- Departing from **liquid solutions** of compound A and sevoflurane in **EtAc**



Liquid
stock solutions

Sevoflurane in EtAc

Compound A in EtAc


Liquid
working dilutions

Liquid
standard solutions

Zero calibrator

Varying concentrations of
Compound A

Transition to
the vapour
phase



5 mL-headspace vial



Validation

■ Linearity

- **Range:** 0 – 75 ppm or $\mu\text{L/L}$ compound A
- Peak area ratio ~ compound A concentration
- **Weighted** linear regression (1/y)

$n^1 = 10$	R square	Slope	Intercept
mean	0.996	0.048	0.018
SD	0.003	0.003	0.003
CV ² (%)	0.3	6.9	16.2

¹ n , number of determinations

² CV, coefficient of variation



■ Other parameters

Validation parameter	Concentration added (ppm or $\mu\text{L/L}$ air)		
	0.5	10	75
Precision (CV¹, %)			
within-day ($n = 6$) ²	9.6	9.9	5.7
total ($n = 10$) ²	10.0	7.1	4.1
Accuracy (recovery, %)			
mean	101.16	101.27	99.00
SD	10.09	6.57	4.10
CV ¹ (%)	9.97	6.49	4.14
LOD (ppm)	0.1		
LOQ (ppm)	0.3		

¹ CV, coefficient of variation

² n , number of determinations



Application

- **Aim** of the investigation

- In-vitro **closed-circuit** anesthesia
- Use of different **CO₂-absorbents**

Classical **soda lime** ↔ alternate products

Sofnolime
Amsorb
LiOH

- Evaluation of **compound A formation**




■ In-vitro set-up

- Closed-circuit Physioflex[®] with model lung
- 2 valves to mimic classical circuit set-up
- Incorporated fan: off
- Sevoflurane_{insp}: 2.2 %
- Duration: 240 min
- 2 mL gas samples for compound A determination in duplicate, at 0, 15, 30, 60, 90, 120, 150, 180, 210 and 240 min




Schematic diagram of the experimental set-up



■ Results

Compound A
inspiratory
concentrations
(ppm)

* $p < .05$ at all
assessments
between groups



Amsorb® (n = 7)


Sofnolime (n = 5)



■ Results

Compound A
inspiratory
concentrations
(ppm)

* $p < .05$ at all
assessments
between groups



LiOH ($n = 7$)

Sodalime ($n = 6$)



■ Results

Sodalime: NaOH + KOH
Sofnolime: NaOH, KOH-free



[Compound A]_{insp}
10 – 35 ppm

Amsorb[®]: Ca(OH)₂ + CaCl₂
LiOH



Practically
NO compound A
formation

➤ Best choice: Amsorb[®]



Conclusions

- Novel, highly sensitive and fully validated assay for vapour phase determination of compound A
- Closed-circuit sevoflurane anesthesia = safe



provided the use of modern anesthesia equipment and products



Acknowledgments

- Department of Anesthesiology,
Ghent University
- Fund for Scientific Research-Flanders

